Alecensa
Chemical Name | alectinib |
Dosage Form | Capsule (oral; 150 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Hoffmann-La Roche |
Approval Year | 2015 |
Indication
- For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).